Business Context and Reporting Period
Company: Evaxion Biotech A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 14, 2025
Context: The filing announces the effective implementation of a previously disclosed change to the company's American Depositary Share (ADS) to ordinary share ratio.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding share structure rather than financial performance.
Material Changes
- ADS Ratio Adjustment: The ratio of American Depositary Shares (ADS) to ordinary shares has changed from 1:10 to 1:50.
- Effective Date: The change became effective on January 14, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the execution of the share ratio change. No unusual items were reported.
Investor Verification Checklist
- Verify the new 1:50 ADS to ordinary share ratio in brokerage accounts and trading platforms.
- Confirm the impact of the ratio change on the per-ADS price and total holdings value.
- Review the full text of the press release (Exhibit 99.1) for any additional details on the rationale for the change.